ANGION BIOMEDICA CORP (ANGN) Stock Price, Quote, News and Overview
NASDAQ:ANGN - Nasdaq - US03476J1079 - Common Stock - Currency: USD
ANGN Quote, Performance and Key Statistics
1
+0.02 (+2.04%)
The current stock price of ANGN is 1 USD. In the past month the price increased by 47.54%. In the past year, price decreased by -36.31%.
ANGN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About ANGN
Company Profile
Angion Biomedica Corp. operates as a biopharmaceutical company. The company is headquartered in Newton, Massachusetts and currently employs 3 full-time employees. The company went IPO on 2021-02-05. The firm is focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases and acute organ injuries. The Company’s product candidates and programs include ANG-3070, a highly selective oral tyrosine kinase receptor inhibitor (TKI) in development as a treatment for fibrotic diseases, a ROCK2 preclinical program targeted towards the treatment of fibrotic diseases, a CYP11B2 preclinical program targeted towards diseases related to aldosterone synthase dysregulation, and a CYP26 (retinoic acid metabolism) inhibitor program targeted towards a number of biopharmaceutical indications, including cancer, and ANG-3777, a hepatocyte growth factor (HGF) mimetic. Its ROCK2 program includes a number of highly selective, oral small molecule inhibitors of ROCK2 developed internally as a potential treatment for fibrotic and other diseases.
Company Info
ANGION BIOMEDICA CORP
7-57 Wells Avenue
Newton MASSACHUSETTS 11553 US
CEO: Jay R. Venkatesan
Employees: 3
Company Website: https://angion.com/
Phone: 18573364001.0
ANGION BIOMEDICA CORP / ANGN FAQ
What is the stock price of ANGION BIOMEDICA CORP today?
The current stock price of ANGN is 1 USD. The price increased by 2.04% in the last trading session.
What is the ticker symbol for ANGION BIOMEDICA CORP stock?
The exchange symbol of ANGION BIOMEDICA CORP is ANGN and it is listed on the Nasdaq exchange.
On which exchange is ANGN stock listed?
ANGN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ANGION BIOMEDICA CORP stock?
6 analysts have analysed ANGN and the average price target is 1.53 USD. This implies a price increase of 53% is expected in the next year compared to the current price of 1. Check the ANGION BIOMEDICA CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ANGION BIOMEDICA CORP worth?
ANGION BIOMEDICA CORP (ANGN) has a market capitalization of 30.11M USD. This makes ANGN a Nano Cap stock.
How many employees does ANGION BIOMEDICA CORP have?
ANGION BIOMEDICA CORP (ANGN) currently has 3 employees.
What are the support and resistance levels for ANGION BIOMEDICA CORP (ANGN) stock?
ANGION BIOMEDICA CORP (ANGN) has a support level at 0.84 and a resistance level at 1.01. Check the full technical report for a detailed analysis of ANGN support and resistance levels.
Is ANGION BIOMEDICA CORP (ANGN) expected to grow?
The Revenue of ANGION BIOMEDICA CORP (ANGN) is expected to decline by -100% in the next year. Check the estimates tab for more information on the ANGN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ANGION BIOMEDICA CORP (ANGN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ANGN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ANGN, evaluating the profitability, health, valuation and growth aspects
- ANGION BIOMEDICA CORP (ANGN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ANGION BIOMEDICA CORP (ANGN) Sales and EPS estimates to see what analysts future expectations are.
- ANGION BIOMEDICA CORP (ANGN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ANGION BIOMEDICA CORP (ANGN) Insider and Institutional Ownership to learn about the owners and their transactions.
- ANGION BIOMEDICA CORP (ANGN) Stock Chart to make your own analysis
- ANGION BIOMEDICA CORP (ANGN) Latest news and press-releases to stay up to date.
Does ANGION BIOMEDICA CORP (ANGN) stock pay dividends?
ANGN does not pay a dividend.
When does ANGION BIOMEDICA CORP (ANGN) report earnings?
ANGION BIOMEDICA CORP (ANGN) will report earnings on 2023-08-14.
What is the Price/Earnings (PE) ratio of ANGION BIOMEDICA CORP (ANGN)?
ANGION BIOMEDICA CORP (ANGN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.29).
ANGN Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ANGN. When comparing the yearly performance of all stocks, ANGN is one of the better performing stocks in the market, outperforming 73.64% of all stocks.
ANGN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ANGN. ANGN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ANGN Financial Highlights
Over the last trailing twelve months ANGN reported a non-GAAP Earnings per Share(EPS) of -1.29. The EPS increased by 38.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
ANGN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to ANGN. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 34.37% and a revenue growth -100% for ANGN